Header Logo

Connection

PEDRO PIEDRA to Influenza, Human

Back to Details
This is a "connection" page, showing publications PEDRO PIEDRA has written about Influenza, Human.
PEDRO PIEDRA
Connection Strength
4.537
Influenza, Human
  1. Understanding the Impact of Resistance to Influenza Antivirals. Clin Microbiol Rev. 2021 03 17; 34(2).
    View in: PubMed
    Score: 0.436
  2. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J. 2020 08; 39(8):700-705.
    View in: PubMed
    Score: 0.420
  3. Live Attenuated Influenza Vaccine: Will the Phoenix Rise Again? Pediatrics. 2019 02; 143(2).
    View in: PubMed
    Score: 0.377
  4. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010 Dec 01; 202(11):1626-33.
    View in: PubMed
    Score: 0.214
  5. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics. 2009 Jul; 124(1):170-8.
    View in: PubMed
    Score: 0.195
  6. Societal and economic consequences of influenza. Manag Care. 2008 Oct; 17(10 Suppl 10):8-14.
    View in: PubMed
    Score: 0.185
  7. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep; 120(3):e553-64.
    View in: PubMed
    Score: 0.171
  8. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005 Feb 18; 23(13):1540-8.
    View in: PubMed
    Score: 0.144
  9. Immunization against viral respiratory disease: a review. Pediatr Infect Dis J. 2004 Nov; 23(11 Suppl):S254-61.
    View in: PubMed
    Score: 0.141
  10. Influenza C virus in U.S. children with acute respiratory infection 2016-2019. J Clin Virol. 2024 10; 174:105720.
    View in: PubMed
    Score: 0.139
  11. Sustained Within-season Vaccine Effectiveness Against Influenza-associated Hospitalization in Children: Evidence From the New Vaccine Surveillance Network, 2015-2016 Through 2019-2020. Clin Infect Dis. 2023 02 08; 76(3):e1031-e1039.
    View in: PubMed
    Score: 0.125
  12. Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan. BMC Pediatr. 2023 01 21; 23(1):35.
    View in: PubMed
    Score: 0.125
  13. Clinical Presentation and Severity of Adenovirus Detection Alone vs Adenovirus Co-detection With Other Respiratory Viruses in US Children With Acute Respiratory Illness from 2016 to 2018. J Pediatric Infect Dis Soc. 2022 Oct 25; 11(10):430-439.
    View in: PubMed
    Score: 0.123
  14. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics. 2002 Oct; 110(4):662-72.
    View in: PubMed
    Score: 0.122
  15. Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment. Clin Infect Dis. 2022 02 11; 74(3):532-540.
    View in: PubMed
    Score: 0.117
  16. Respiratory Viral Infections and Infection Prevention Practices Among Women With Acute Respiratory Illness During Delivery Hospitalizations During the 2019-2020 Influenza Season. J Infect Dis. 2022 01 05; 225(1):50-54.
    View in: PubMed
    Score: 0.116
  17. Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study. Pediatr Infect Dis J. 2020 08; 39(8):706-712.
    View in: PubMed
    Score: 0.105
  18. Remote Laboratory Management: Respiratory Virus Diagnostics. J Vis Exp. 2019 04 06; (146).
    View in: PubMed
    Score: 0.096
  19. Influenza virus infections in infants. Pediatr Infect Dis J. 1997 Nov; 16(11):1065-8.
    View in: PubMed
    Score: 0.087
  20. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016 10 01; 214(7):1010-9.
    View in: PubMed
    Score: 0.078
  21. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15; 213(10):1546-56.
    View in: PubMed
    Score: 0.077
  22. Influenza virus pneumonia: pathogenesis, treatment, and prevention. Semin Respir Infect. 1995 Dec; 10(4):216-23.
    View in: PubMed
    Score: 0.076
  23. Factors associated with real-time RT-PCR cycle threshold values among medically attended influenza episodes. J Med Virol. 2016 Apr; 88(4):719-23.
    View in: PubMed
    Score: 0.075
  24. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15; 211(10):1529-40.
    View in: PubMed
    Score: 0.071
  25. Detection of NH1N1 influenza virus in nonrespiratory sites among children. Pediatr Infect Dis J. 2014 Jan; 33(1):95-6.
    View in: PubMed
    Score: 0.067
  26. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
    View in: PubMed
    Score: 0.066
  27. Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised). BMC Res Notes. 2013 May 03; 6:177.
    View in: PubMed
    Score: 0.064
  28. [Universal immunisation against influenza in paediatrics, yes or no?]. An Pediatr (Barc). 2013 Oct; 79(4):261.e1-261.e11.
    View in: PubMed
    Score: 0.063
  29. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008 May; 27(5):444-52.
    View in: PubMed
    Score: 0.045
  30. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine. 2007 Nov 19; 25(47):8010-20.
    View in: PubMed
    Score: 0.043
  31. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007 May 16; 25(20):4038-45.
    View in: PubMed
    Score: 0.042
  32. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005 Sep; 116(3):e397-407.
    View in: PubMed
    Score: 0.037
  33. Sequencing-Based Detection of Avian Influenza A(H5N1) Virus in Wastewater in Ten Cities. N Engl J Med. 2024 09 26; 391(12):1157-1159.
    View in: PubMed
    Score: 0.035
  34. Safety of cold-adapted live influenza vaccine. Pediatr Infect Dis J. 2004 Jun; 23(6):593-4; author reply 594.
    View in: PubMed
    Score: 0.034
  35. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004 Jan; 158(1):65-73.
    View in: PubMed
    Score: 0.033
  36. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003 Aug 15; 158(4):305-11.
    View in: PubMed
    Score: 0.032
  37. Comparative analysis of three multiplex platforms for the detection of respiratory viral pathogens. J Clin Virol. 2022 11; 156:105274.
    View in: PubMed
    Score: 0.030
  38. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000 Feb; 136(2):168-75.
    View in: PubMed
    Score: 0.025
  39. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998 May 14; 338(20):1405-12.
    View in: PubMed
    Score: 0.023
  40. Cytotoxic T lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine. J Med Virol. 1996 Oct; 50(2):105-11.
    View in: PubMed
    Score: 0.020
  41. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J Infect Dis. 1996 Jun; 173(6):1313-9.
    View in: PubMed
    Score: 0.020
  42. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine. 1993; 11(7):718-24.
    View in: PubMed
    Score: 0.016
  43. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol. 1991 Feb 01; 133(3):296-304.
    View in: PubMed
    Score: 0.014
  44. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect. 2005 May; 50(4):322-30.
    View in: PubMed
    Score: 0.009
  45. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000 Jan 26; 283(4):499-505.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.